Prepare to administer dantrolene promptly if malignant hyperthermia symptoms develop
🧯 Dantrolene is the specific medication used to treat a malignant hyperthermia crisis because it reduces abnormal calcium release from skeletal muscle.
🧯 Prompt administration helps decrease muscle contraction, heat production, hypermetabolism, and associated metabolic complications.
🧯 Dantrolene must be readily available wherever triggering anesthetic agents are administered.
🧯 Treatment is most effective when initiated rapidly at the first signs of malignant hyperthermia.
🧯 Therefore, ensuring immediate access to dantrolene is essential for safe perioperative management of susceptible clients.
Communicate the patient's risk of malignant hyperthermia to the surgical and anesthesia teams
🧯 Clear communication of malignant hyperthermia susceptibility allows the anesthesia team to select nontriggering anesthetic agents.
🧯 Triggering agents such as certain volatile inhaled anesthetics and succinylcholine should be avoided in susceptible individuals.
🧯 Advance notification also ensures that emergency medications, cooling measures, laboratory support, and monitoring are available if needed.
🧯 Interprofessional communication reduces the chance of accidental exposure to a known trigger.
🧯 Therefore, informing the entire perioperative team is a critical preventive nursing action.
Assess and document detailed family history of malignant hyperthermia prior to surgery
🧯 Malignant hyperthermia susceptibility can be inherited, so a detailed family history is an important component of preoperative assessment.
🧯 A history of anesthesia-related unexplained fever, muscle rigidity, cardiac arrest, or known malignant hyperthermia in relatives should be documented clearly.
🧯 Identifying familial risk before surgery allows the anesthesia plan to be modified appropriately.
🧯 Documentation also helps ensure that future healthcare professionals recognize the client's potential susceptibility.
🧯 Therefore, obtaining and recording a detailed family history supports both prevention and long-term patient safety.
Place an allergy or alert band on the patient indicating susceptibility to malignant hyperthermia
🧯 An alert band provides a visible warning that the client is at risk for a potentially life-threatening anesthetic reaction.
🧯 The alert reinforces written documentation and communication among nurses, surgeons, anesthesia personnel, and other perioperative staff.
🧯 It decreases the possibility that triggering medications will be administered inadvertently.
🧯 Such identification is particularly important if the client is sedated, unconscious, or unable to communicate during perioperative care.
🧯 Therefore, placing a clearly visible alert is an appropriate additional safety measure for a susceptible client.